Man adding pills into a coating machine.
Press release
Health Care
August 16, 2021

Evonik opens new lab in Istanbul to increase offerings of oral drug delivery solutions

  • Expansion of Evonik’s Health Care business in Turkey, Middle East & Africa
  • Focus on oral drug delivery solutions with EUDRAGIT® functional polymers
  • Laboratory to support product development, scale up and production

Istanbul, Turkey. Evonik opens a new lab in Istanbul to provide oral drug delivery solutions in Turkey, the Middle East and Africa. The new lab will support pharmaceutical companies with product development, scale up and production, and offer personalized training sessions. The lab strengthens the growth of Evonik’s Health Care business in the Middle East & Africa (MEA) region.


As part of the Technical Competence Centre at Evonik’s site in Istanbul, the new lab will form part of a continuous expansion of the facility. The development will enable Evonik’s Health Care business to deliver solutions to customers in Turkey and throughout the Middle East, making use of local technical teams.


“Having experts on the ground to support our customers based in Turkey and the Middle East will mean that we can provide swift support in local languages, while more easily navigating complex customs requirements. The location of the lab will increase product development projects with our customers and drive market penetration in the region,” says Tuğçe Yenigun, business manager at Evonik Health Care in Turkey.


One focus of the lab is Evonik’s EUDRAGIT®, the industry’s preferred portfolio of functional polymers for use with oral drug products that have an immediate, delayed or sustained release profile. The breadth, versatility and history of EUDRAGIT®, combined with Evonik’s range of drug delivery technologies, formulation and cGMP manufacturing services, provide pharmaceutical companies with unrivalled safety and functional reliability for their oral solid dosage forms.


Another solution offered at the new lab is EUDRAGUARD®, the broad toolkit of polymers which has been developed for site-specific delivery of nutraceuticals to improve bioavailability and uptake in the human body.


Evonik’s new lab is based in Tuzla in the east of Istanbul. It was founded in 1987, and today is a Business and Technical Competence Center for Turkey as well as for defined export markets further afield such as Azerbaijan, Pakistan, and Israel.


Evonik Health Care, which is part of the Nutrition & Care division of Evonik, is one of the world’s leading CDMOs (Contract Development and Manufacturing Organization) for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also a supplier and CDMO for active pharmaceutical ingredients (APIs), amino acids, cell culture ingredients, and medical device excipients.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.